Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors  by Chaari, Anis et al.
International Journal of Infectious Diseases 17 (2013) e1225–e1228Acinetobacter baumannii ventilator-associated pneumonia:
epidemiology, clinical characteristics, and prognosis factors
Anis Chaari a,*, Basma Mnif b, Mabrouk Bahloul a, Fouzia Mahjoubi b, Kamilia Chtara a,
Olfa Turki a, Nourhene Gharbi a, Hedi Chelly a, Adnene Hammami b, Mounir Bouaziz a
a Intensive Care Unit, Faculty of Medicine, University of Sfax, Hoˆpital Habib Bourguiba, Route el Ain Km 1, 3029 Sfax, Tunisia
bDepartment of Microbiology, Faculty of Medicine, University of Sfax, Sfax, Tunisia
A R T I C L E I N F O
Article history:
Received 3 May 2013
Received in revised form 27 June 2013
Accepted 19 July 2013







S U M M A R Y
Objective: The aim of this study was to describe the epidemiological characteristics of Acinetobacter
baumannii ventilator-associated pneumonia (VAP) and to identify factors predictive of a poor outcome.
Methods: A retrospective study was conducted over 16 months in a Tunisian intensive care unit (ICU). All
adult patients with A. baumannii VAP were included.
Results: Ninety-two patients were included in they study; 41 (44.6%) were admitted because of multiple
trauma. The mean age of the patients was 44.5  19.5 years. All patients needed mechanical ventilation on
admission. The mean SAPS II score was 39  15. The mean delay before VAP onset was 8.1  4.7 days. On VAP
onset, 57 patients (62%) developed septic shock. Only 14.2% of isolated strains were susceptible to imipenem;
none were resistant to colistin. The mean duration of mechanical ventilation was 20  11 days. The mean
duration of ICU stay was 24.3  18.7 days. ICU mortality was 60.9%. In the multivariate analysis, factors
predictive of a poor outcome were previously known hypertension (odds ratio 5.8, 95% conﬁdence interval
1.4–24.9; p = 0.018) and VAP-related septic shock (odds ratio 8.5, 95% conﬁdence interval 3–23.7; p < 0.001).
Conclusion: A. baumannii VAP is associated with a high mortality. Hemodynamic impairment is
predictive of a poor outcome.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Ventilator-associated pneumonia (VAP) is a frequent nosoco-
mial infection in critically ill patients, with a high mortality rate,
reaching up to 33–50%.1,2 During recent decades, Acinetobacter
baumannii, a microorganism characterized by rapid development
of resistance to the majority of antimicrobials, has emerged as a
pathogen frequently incriminated in lower respiratory tract
infections in critically ill patients.3,4 Data available in the literature
reveal an important disparity in bacterial ecology between
countries. A. baumannii is known to be endemic in countries of
North Africa and the Middle East.5,6 However, several outbreaks
have also been reported in European countries.7,8 Recently, we
reported that A. baumannii was responsible for 29.4% of VAP in our
intensive care unit (ICU), coming in second to Pseudomonas
aeruginosa.9 Even though the hallmark of A. baumannii VAP is its
multidrug resistance, the prognostic impact of this complication
remains controversial and results have been conﬂicting.3,10
Moreover, factors predictive of a poor outcome have rarely been* Corresponding author. Tel.: +216 26349334; fax: +216 74243427.
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epidemiological and clinical characteristics of A. baumannii VAP
and to identify factors predictive of a poor outcome in critically ill
patients who develop this nosocomial complication.
2. Patients and methods
2.1. Study design
This retrospective observational study was conducted from
August 1, 2010 to November 30, 2011 in our medical surgical ICU
(Habib Bourguiba Hospital, Sfax, Tunisia). The study was approved
by the local ethics board.
2.2. Patients
All medical ﬁles of patients older than 15 years admitted to the
ICU were reviewed retrospectively. We included in our study all
patients with conﬁrmed A. baumannii VAP. VAP was deﬁned as
pneumonia that occurred within 48 h after commencing mechani-
cal ventilation.2 Pneumonia was deﬁned according to the criteria of
the US Centers for Disease Control and Prevention. The diagnosis
required two or more of the following criteria to be met: (1) feverses. Published by Elsevier Ltd. All rights reserved.
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(25% increase and 10  109/l) or leukopenia (25% decrease and
5  109/l); and (3) purulent tracheal secretion (>25% neutrophils
per high-power ﬁeld). It also required one of the following criteria
to be met: (1) new or persistent inﬁltration on chest radiography;
(2) some microorganisms isolated from pleural effusion and
tracheal secretion; (3) radiographic cavitation or histological
evidence of pneumonia pathogens; or (4) positive sputum culture
from a quantitative bacterial bronchoalveolar lavage (BAL) culture
of 105 colony-forming units (CFU)/ml.11 In our study, the diagnosis
needed to be conﬁrmed with a lower respiratory tract sample using
a quantitative culture with a predeﬁned positive threshold of 104
CFU/ml for BAL. Patients with a positive culture lower than the
predeﬁned threshold, those with no clinical symptoms, and/or
those without radiological evidence of an alveolar inﬁltrate were
considered to have A. baumannii colonization and were excluded
from the study.
2.3. Data collection
Demographic, clinical, and biological ﬁndings on admission
were obtained from the patients’ medical charts and reviewed
retrospectively. Clinical severity was assessed using the Simpliﬁed
Acute Physiology Score (SAPS II), The Glasgow Coma Scale (GCS)
and the Sequential Organ Failure Assessment (SOFA) score.12,13 In
trauma patients, the severity of injury was assessed by the Injury
Severity Score (ISS).14 We also recorded the delay in onset of A.
baumannii VAP and the susceptibility of isolated strains to
antimicrobial agents. Antibiotics received before VAP onset were
mentioned for each patient included. Clinical severity at VAP onset
was evaluated using the SOFA score.13 For each patient, we noted
the delay in appropriate antimicrobial therapy as well as the
duration of this therapy. Antimicrobial treatment was considered
as appropriate if at least one agent was active against the isolated
strain of A. baumannii. After culture results were known, the
antimicrobial regimen was maintained or adapted on the basis of
sensitivity testing.
2.4. Follow-up and outcome
All patients were followed up until death or ICU discharge. For
each patient, we recorded further nosocomial events, the duration
of mechanical ventilation, and the length of ICU stay (LOS).
2.5. Statistical analysis
Qualitative variables were expressed as percentages, whereas
quantitative variables were expressed as means  standard
deviations or medians. Univariate analysis comparing survivors
and non-survivors was performed in order to identify factors
signiﬁcantly correlated with mortality. Qualitative variables wereTable 1
Biological ﬁndings on admission
Parameters n Median Mea
pH 92 7.37 7
PaCO2 (mmHg) 92 35 36
PaO2 (mmHg) 92 125 131
[HCO3
] (mmol/l) 92 20 20
SaO2 (%) 92 98.3 97
PaO2/FiO2 (mmHg) 92 234 245
Leukocytes (109/l) 92 13.750 14
Hb (g/dl) 92 10.7 10
Platelet count (109/l) 92 164.5 179
BUN (mmol/l) 92 8 11
Creatinine (mmol/l) 92 102 162
Hb, hemoglobin; BUN, blood urea nitrogen.compared using the Chi-square test or Fisher’s exact test, whereas all
quantitative variables were compared by t-test or Mann–Whitney
test, as appropriate. The normal distribution of quantitative variables
was checked using the Kolmogorov–Smirnov test. All tests were two-
sided. The level of signiﬁcance was set at p < 0.05. Variables were
then subjected to a multivariate analysis with a logistic regression
procedure and forward stepwise selection of p < 0.10, in order to
identify independent factors predicting death in critically ill patients
suffering A. baumannii VAP. Odds ratios (OR) were calculated with
95% conﬁdence intervals (95% CI). SPSS version 18 was used for the
statistical analyses (SPSS Inc., Chicago, IL, USA).
3. Results
Between September 1, 2009 and November 30, 2011, 2197
adult patients were admitted to our ICU. A baumannii was isolated
in the BAL in 111 (5%) cases, but the diagnostic criteria for VAP
were fulﬁlled in only 92 patients (4.2%); these patients were
included in our study.
3.1. Baseline characteristics and therapeutic management on
admission
The mean age of the patients was 44.5  19.5 years (ranging
from 18 to 91 years). The male to female sex ratio was 2.1. Forty-one
patients (44.6%) were admitted because of multiple trauma, 24
(26.1%) were admitted because of acute respiratory failure, and seven
patients (7.6%) were admitted for postoperative care. Other causes
leading to ICU admission were coma for 13 patients (14.1%) and
severe hypotension for seven patients (7.6%). Fourteen patients
(15.2%) had a previous history of chronic obstructive pulmonary
disease (COPD), and diabetes mellitus and/or hypertension were
known in 36 patients (39.1%). The mean SAPS II was 39  15 and the
mean SOFA score was 8  5, and the mean ISS was 48  24 in trauma
patients. On admission, 57 patients (62%) were hypotensive and
needed vasopressor support. The mean Glasgow Coma Scale (GCS)
score was 10  4. Mechanical ventilation was instituted within the
ﬁrst 24 h in all cases. Eighty-eight patients (95.7%) received curative
or prophylactic postoperative antimicrobial therapy. Amoxicillin–
clavulanic acid was given to 45 patients (48.9%).
Biological ﬁndings on admission are summarized in Table 1.
3.2. A. baumannii VAP characteristics
The mean delay to VAP onset regarding mechanical ventilation
was 8.1  4.7 days (ranging from 3 to 32 days). Before VAP, 26
patients (28.3%) were re-intubated and 27 patients (29.3%) required a
surgical tracheotomy. Moreover, at onset of VAP, 81 patients (88%)
were receiving antimicrobial agents and 16 patients (17.4%)
developed this nosocomial event while receiving imipenem. At onset
of VAP, 19 patients were receiving cefotaxime (20.7%), 32 weren SD Minimum Maximum
.35 0.12 6.96 7.61
 9.8 18 90.6
 51 52 269
 5.2 6.7 40
 3.7 82 100
 109 81 500
.270 6.134 1.800 28.000
.8 2.7 4.9 16.2
.7 92 27 472
.7 10.3 2.5 46.8
 138 30 624
Figure 1. Antimicrobial susceptibility of isolated strains. The number of strains
tested for antimicrobial susceptibility was 92. AZT, aztreonam; CIP, ciproﬂoxacin;
AMK, amikacin; RMP, rifampin; CS, colistin; TZP, piperacillin–tazobactam; PIP,
piperacillin; IMP, imipenem.
Table 2







Age, years, mean  SD 40.3  16.8 47.2  20.8 0.095
Previous diabetes mellitus, n/% 3/8.3 13/23.2 0.092
Previous hypertension, n /% 3/8.3 17/30.4 0.018
SAPS II, mean  SD 39  17 40  14 0.764
SOFA score, mean  SD 8.5  7 8  3.5 0.569
Shock, n /% 21/38.2 34/61.8 0.82
GCS, mean  SD 9  4 11  4 0.011
pH, mean  SD 7.34  0.13 7.35  0.11 0.53
PaCO2, mmHg, mean  SD 35.9  8 36.2  10.9 0.885
PaO2, mmHg, mean  SD 146  54 132  47 0.125
Bicarbonates, mmol/l, mean  SD 19.2  4.7 20.3  5.5 0.352
SaO2, %, mean  SD 97.6  2.8 96  4.2 0.14
PaO2/FiO2, mmHg, mean  SD 264  118 231  101 0.156
Leukocytes, 109/l, mean  SD 14.350  6.458 14.217  5.975 0.92
Platelets, 109/l, mean  SD 177.8  87 181  96 0.869
SD, standard deviation; SAPS II, Simpliﬁed Acute Physiology Score II; SOFA,
Sequential Organ Failure Assessment; GCS, Glasgow Coma Scale.
Table 3
Multivariate analysis of factors predicting ICU mortality
Factors p-Value OR 95% CI
Minimum Maximum
Previously known hypertension 0.018 5.8 1.4 24.9
Trauma 0.767 0.84 0.03 4.7
SOFA score >7 at VAP onset 0.58 1.47 0.37 5.9
VAP-related septic shock < 0.001 8.5 3 23.7
PaO2/FiO2 <250 mmHg at VAP onset 0.164 2.3 0.7 7.2
Creatinine >150 mmol/l at VAP onset 0.874 1.2 0.23 3.5
Delay of appropriate antimicrobial
treatment >2 days
0.979 1.01 0.33 3.1
ICU, intensive care unit; OR, odds ratio; CI, conﬁdence interval; SOFA, Sequential
Organ Failure Assessment; VAP, ventilator-associated pneumonia.
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ﬂuoroquinolones (19.6%), and only two patients were receiving
amikacin (2.1%). Microbiological ﬁndings showed that 85.8% of
isolated strains were resistant to imipenem, whereas no resistance to
colistin was recorded (Figure 1).
On clinical examination, mean temperature was 38.3  1.6 8C.
Fifty-seven patients (62%) experienced septic shock requiring
vasopressor support. The alveolar inﬁltrate was unilateral in 58
cases (63%). Associated pleural effusion was found in 10 patients
(10.9%), and six patients (6.9%) developed a pulmonary abscess.
Appropriate antimicrobial therapy was instituted within 1.8  1.6
days regarding VAP onset (range 0–5 days). Colistin was the agent
most used as the empirical antibiotic, as it was given to 86 patients
(93.5%). When microbiological results were obtained, colistin was
introduced or continued in combination with rifampin in six cases
(6.5%) and with imipenem in 96 (93.5%) cases. The mean duration of
antimicrobial treatment was 10.6  6.6 days. Only nine patients
(9.8%) had an associated A. baumannii bloodstream infection. Further
relapse of A. baumannii VAP was recorded in three patients (3.3%).
3.3. Prognosis factors
The mean duration of mechanical ventilation was 20  11 days
(ranging from 6 to 55 days). The mean duration of ICU LOS was
24.3  18.7 days. Fifty-six deaths were recorded in the ICU (60.9%).
ICU mortality was signiﬁcantly lower in trauma patients (19/41 vs.
37/51; p = 0.01). GCS was signiﬁcantly lower in survivors (9  4 vs.
11  4; p = 0.011). Patients with known hypertension had a
signiﬁcantly higher mortality compared with the other patients
(17/20 and 39/72, respectively; p = 0.018). No signiﬁcant difference
was found between survivors and non-survivors regarding the
remaining clinical and biological baseline characteristics (Table 2).
The mean delay to onset of VAP was similar in the two groups
studied: 7.9  4 days in survivors and 8.2  5.2 days in non-survivors
(p = 0.778). However, mortality was signiﬁcantly higher in patients
with VAP complicated by septic shock needing vasopressors (44/57
(77.2%) vs. 12/35 (34.3%); p < 0.001). Similarly, the SOFA score at VAP
onset was signiﬁcantly higher in those who died compared to the
survivors (8.4  2.8 vs. 6.5  3.1; p = 0.004). Biological ﬁndings at VAP
onset showed that patients with a poor outcome had lower PaO2/FiO2
ratios (209  104 vs. 265  122 mmHg; p = 0.021), higher blood urea
nitrogen levels (16.7  12.1 vs. 10.6  7.8 mmol/l; p = 0.004), and
higher serum creatinine levels (156  114 vs. 112  94 mmol/l;
p = 0.049). However, leukocyte and platelet counts were similar in
the two groups studied. Moreover, A. baumannii susceptibility to
imipenem had no impact on ICU mortality. In fact, mortality was
61.5% in patients with sensitive strains and 60.8% in patients withresistant strains (p = 0.733). Moreover, when analyzing the antimi-
crobial agents that our patients were receiving at VAP onset, we found
that ICU mortality was signiﬁcantly lower in patients who were
receiving amoxicillin–clavulanic acid (46.9% vs. 70.2%; p = 0.03),
whereas no correlation was found for the other agents. Appropriate
antimicrobial treatment was also instituted with a similar delay
regarding VAP onset: 1.8  1.7 days in survivors and 1.8  1.6 days in
non-survivors (p = 0.979). In the multivariate analysis, independent
factors predicting a poor outcome were previously known hyperten-
sion (OR 5.8, 95% CI 1.4–24.9; p = 0.018) and VAP-related septic shock
(OR 8.5, 95% CI 3–23.7; p < 0.001) (Table 3).
4. Discussion
Multidrug-resistant organisms are a growing concern in the
ICU. Critically ill patients who develop VAP experience increased
morbidity and mortality.15 In 1993, Fagon et al. reported that for
pneumonia caused by Pseudomonas aeruginosa or Acinetobacter
spp, the attributable mortality was as high as 42.8%, with a relative
risk of death of 2.5.10 Available data in the literature suggest that
mortality related to this nosocomial event varies from 26% to
68%.10,16,17 Even though the reported mortality is high, only a few
studies have been conducted to identify factors predictive of a poor
outcome in patients developing this nosocomial event. Our results
show septic shock and previous hypertension to be independent
factors predicting a poor outcome. Whether or not these ﬁndings
are speciﬁc to A. baumannii VAP cannot be formally established. In
fact, Lisboa et al., in a prospective observational study including
441 VAP episodes, reported that septic shock was an independent
factor predicting ICU mortality (OR 4.4, 95% CI 2.71–7.15). Unlike in
A. Chaari et al. / International Journal of Infectious Diseases 17 (2013) e1225–e1228e1228our study, Lisboa et al. included VAP episodes due to
heterogeneous microorganisms and A. baumannii represented
only 10.9% of all isolates.18 Thus, the identiﬁcation of previous
hypertension as an independent factor associated with a poor
outcome may be explained by a worse tolerance of hemody-
namic impairment with more organ dysfunction compared
with other patients.
Studies aimed at identifying predictive factors in ICU patients
with A. baumannii VAP remain scarce. Chang et al. reported the
following to be independent factors predicting 30-day in-hospital
mortality in ICU patients with A. baumannii VAP: creatinine
>1.6 mg/dl, inadequacy of initial antimicrobial therapy, CURB
score 3, and C-reactive protein 120 mg/l.11 Garnacho-Montero
et al., in a prospective study including 81 episodes of VAP in
critically ill patients, reported that the SOFA score on the day of
VAP diagnosis was the only predictor of in-hospital mortality.
Among all these episodes, 41 were due to A. baumannii.
Interestingly, the authors reported that there was no signiﬁcant
difference in mortality related to the causative microorganisms
(58.5% in patients with A. baumannii VAP vs. 65.9% in patients with
VAP caused by other pathogens; p = 0.3).3
Inadequate empirical therapy of VAP is an independent
predictor of mortality in heterogeneous populations of ICU
patients.3,19 This rule is also true in critically ill patients developing
A. baumannii VAP.19 In our study, the mean delay to the institution
of appropriate antibiotic therapy was similar between survivors
and non-survivors. This may be explained by the fact that in almost
all cases, empirical antimicrobial therapy included colistin. This
drug was chosen as a ﬁrst-line antibiotic regimen in accordance
with our local microbiological ecology.20 In our study, colistin was
given in combination with imipenem or with rifampin, as such
associations have been reported to be synergic and prevent the
development of colistin-resistant mutants.21
Even though factors predictive of a poor outcome related to A.
baumannii VAP in critically ill patients have rarely been
investigated, several limitations of our work should be men-
tioned. First, the retrospective nature of our study did not allow us
to estimate the mortality attributable to this nosocomial event
and only ICU mortality was recorded. Second, we included a
heterogeneous population with different causes leading to ICU
admission. Studies focusing on particular subgroups, such as
trauma patients, may identify other predictive factors of a poor
outcome more accurately. In fact, antimicrobial therapy was not
standardized according to the susceptibility of the isolated
strains.
In conclusion, hemodynamic impairment is particularly asso-
ciated with a poor outcome in critically ill patients with A.
baumannii VAP. In ICUs where this pathogen is endemic, empirical
antibiotic therapy should include drugs that are effective according
to the microbiological ecology. In Tunisian ICUs, colistin appears to
be an appropriate ﬁrst-line antimicrobial drug in critically ill
patients developing late-onset VAP.
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